Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 317

1.

Multiple Knockout of Classical HLA Class II β-Chains by CRISPR/Cas9 Genome Editing Driven by a Single Guide RNA.

Crivello P, Ahci M, Maaßen F, Wossidlo N, Arrieta-Bolaños E, Heinold A, Lange V, Falkenburg JHF, Horn PA, Fleischhauer K, Heinrichs S.

J Immunol. 2019 Jan 30. pii: ji1800257. doi: 10.4049/jimmunol.1800257. [Epub ahead of print]

PMID:
30700588
2.

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M.

J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14.

3.

CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.

van Balen P, van Bergen CAM, van Luxemburg-Heijs SAP, de Klerk W, van Egmond EHM, Veld SAJ, Halkes CJM, Zwaginga JJ, Griffioen M, Jedema I, Falkenburg JHF.

Front Immunol. 2018 Dec 18;9:3016. doi: 10.3389/fimmu.2018.03016. eCollection 2018.

4.

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy.

Luk SJ, van der Steen DM, Hagedoorn RS, Jordanova ES, Schilham MW, Bovée JV, Cleven AH, Falkenburg JF, Szuhai K, Heemskerk MH.

Oncoimmunology. 2018 Sep 11;7(12):e1507600. doi: 10.1080/2162402X.2018.1507600. eCollection 2018.

5.

Dissecting Genetic Control of HLA-DPB1 Expression and Its Relation to Structural Mismatch Models in Hematopoietic Stem Cell Transplantation.

Meurer T, Arrieta-Bolaños E, Metzing M, Langer MM, van Balen P, Falkenburg JHF, Beelen DW, Horn PA, Fleischhauer K, Crivello P.

Front Immunol. 2018 Oct 5;9:2236. doi: 10.3389/fimmu.2018.02236. eCollection 2018.

6.

Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy.

Mousset CM, Hobo W, Ji Y, Fredrix H, De Giorgi V, Allison RD, Kester MGD, Falkenburg JHF, Schaap NPM, Jansen JH, Gattinoni L, Dolstra H, van der Waart AB.

Oncoimmunology. 2018 Aug 6;7(10):e1488565. doi: 10.1080/2162402X.2018.1488565. eCollection 2018.

7.

The allogeneic HLA-DP-restricted T-cell repertoire provoked by allogeneic dendritic cells contains T cells that show restricted recognition of hematopoietic cells including primary malignant cells.

Laghmouchi A, Hoogstraten C, van Balen P, Falkenburg JHF, Jedema I.

Haematologica. 2019 Jan;104(1):197-206. doi: 10.3324/haematol.2018.193680. Epub 2018 Sep 20.

8.

Immune surveillance by autoreactive CD4-positive helper T cells is a common phenomenon in patients with acute myeloid leukemia.

Lam TS, van de Meent M, Marijt EWA, Falkenburg JHF, Jedema I.

Eur J Haematol. 2018 Aug 4. doi: 10.1111/ejh.13157. [Epub ahead of print]

PMID:
30076646
9.

Natural T-cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles.

Kremer AN, Zonneveld MI, Kremer AE, van der Meijden ED, Falkenburg JHF, Wauben MHM, Nolte-'t Hoen ENM, Griffioen M.

Eur J Immunol. 2018 Oct;48(10):1621-1631. doi: 10.1002/eji.201747152. Epub 2018 Aug 17.

10.

CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity.

van der Heiden PLJ, van Egmond HM, Veld SAJ, van de Meent M, Eefting M, de Wreede LC, Halkes CJM, Falkenburg JHF, Marijt WAF, Jedema I.

Transpl Immunol. 2018 Aug;49:54-58. doi: 10.1016/j.trim.2018.04.003. Epub 2018 Apr 18.

PMID:
29679650
11.

A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells.

Luimstra JJ, Garstka MA, Roex MCJ, Redeker A, Janssen GMC, van Veelen PA, Arens R, Falkenburg JHF, Neefjes J, Ovaa H.

J Exp Med. 2018 May 7;215(5):1493-1504. doi: 10.1084/jem.20180156. Epub 2018 Apr 17.

12.

Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.

Bijen HM, van der Steen DM, Hagedoorn RS, Wouters AK, Wooldridge L, Falkenburg JHF, Heemskerk MHM.

Mol Ther. 2018 May 2;26(5):1206-1214. doi: 10.1016/j.ymthe.2018.02.017. Epub 2018 Feb 23.

PMID:
29567312
13.

Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction.

van Balen P, van der Zouwen B, Kruisselbrink AB, Eefting M, Szuhai K, Jordanova ES, Falkenburg JHF, Jedema I.

Front Immunol. 2018 Feb 27;9:331. doi: 10.3389/fimmu.2018.00331. eCollection 2018.

14.

Alloreactive T Cell Receptor Diversity against Structurally Similar or Dissimilar HLA-DP Antigens Assessed by Deep Sequencing.

Arrieta-Bolaños E, Crivello P, Metzing M, Meurer T, Ahci M, Rytlewski J, Vignali M, Yusko E, van Balen P, Horn PA, Falkenburg JHF, Fleischhauer K.

Front Immunol. 2018 Feb 19;9:280. doi: 10.3389/fimmu.2018.00280. eCollection 2018.

15.

The simultaneous isolation of multiple high and low frequent T-cell populations from donor peripheral blood mononuclear cells using the major histocompatibility complex I-Streptamer isolation technology.

Roex MCJ, Hageman L, Heemskerk MT, Veld SAJ, van Liempt E, Kester MGD, Germeroth L, Stemberger C, Falkenburg JHF, Jedema I.

Cytotherapy. 2018 Apr;20(4):543-555. doi: 10.1016/j.jcyt.2018.01.008. Epub 2018 Feb 12.

PMID:
29449085
16.

High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor-/CD52- T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell-Depleted Allogeneic Stem Cell Transplantation.

Loeff FC, Falkenburg JHF, Hageman L, Huisman W, Veld SAJ, van Egmond HME, van de Meent M, von dem Borne PA, Veelken H, Halkes CJM, Jedema I.

J Immunol. 2018 Mar 15;200(6):2199-2208. doi: 10.4049/jimmunol.1701018. Epub 2018 Feb 2.

PMID:
29427418
17.

The Importance of Parental Connectedness and Relationships With Healthcare Professionals in End-of-Life Care in the PICU.

Falkenburg JL, Tibboel D, Ganzevoort RR, Gischler SJ, van Dijk M.

Pediatr Crit Care Med. 2018 Mar;19(3):e157-e163. doi: 10.1097/PCC.0000000000001440.

PMID:
29329163
18.

Specific T Cell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell Surface.

Bijen HM, Hassan C, Kester MGD, Janssen GMC, Hombrink P, de Ru AH, Drijfhout JW, Meiring HD, de Jong AP, Falkenburg JHF, Jimenez CR, Heemskerk MHM, van Veelen PA.

Proteomics. 2018 Jun;18(12):e1700250. doi: 10.1002/pmic.201700250. Epub 2018 Feb 23.

PMID:
29251415
19.

Graft versus tumor effects and why people relapse.

Falkenburg JHF, Jedema I.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):693-698. doi: 10.1182/asheducation-2017.1.693. Review.

20.

Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation.

Hutten TJA, Norde WJ, Woestenenk R, Wang RC, Maas F, Kester M, Falkenburg JHF, Berglund S, Luznik L, Jansen JH, Schaap N, Dolstra H, Hobo W.

Biol Blood Marrow Transplant. 2018 Apr;24(4):666-677. doi: 10.1016/j.bbmt.2017.11.027. Epub 2017 Dec 26.

PMID:
29197680
21.

Donor T-cell responses and disease progression patterns of multiple myeloma.

Eefting M, de Wreede LC, Von dem Borne PA, Halkes CJM, Kersting S, Marijt EWA, Putter H, Veelken H, Schetelig J, Falkenburg JHF.

Bone Marrow Transplant. 2017 Dec;52(12):1609-1615. doi: 10.1038/bmt.2017.201. Epub 2017 Oct 2.

PMID:
28967897
22.

Long-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin.

van der Hem JGK, de Wreede LC, Brand A, Veelken H, Falkenburg JHF, Halkes CJM.

Haematologica. 2017 Oct;102(10):e382-e383. doi: 10.3324/haematol.2017.171215. Epub 2017 Jul 13. No abstract available.

23.

An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.

Zimmermannova O, Doktorova E, Stuchly J, Kanderova V, Kuzilkova D, Strnad H, Starkova J, Alberich-Jorda M, Falkenburg JHF, Trka J, Petrak J, Zuna J, Zaliova M.

Oncogene. 2017 Oct 26;36(43):5985-5994. doi: 10.1038/onc.2017.210. Epub 2017 Jun 26.

24.

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.

Franssen LE, Roeven MWH, Hobo W, Doorn R, Oostvogels R, Falkenburg JHF, van de Donk NW, Kester MGD, Fredrix H, Westinga K, Slaper-Cortenbach I, Spierings E, Kersten MJ, Dolstra H, Mutis T, Schaap N, Lokhorst HM.

Bone Marrow Transplant. 2017 Oct;52(10):1378-1383. doi: 10.1038/bmt.2017.118. Epub 2017 Jun 5.

PMID:
28581468
25.

Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivo.

Thordardottir S, Schaap N, Louer E, Kester MG, Falkenburg JH, Jansen J, Radstake TR, Hobo W, Dolstra H.

Oncoimmunology. 2017 Feb 6;6(3):e1285991. doi: 10.1080/2162402X.2017.1285991. eCollection 2017.

26.

Mismatched HLA-DRB3 Can Induce a Potent Immune Response After HLA 10/10 Matched Stem Cell Transplantation.

van Balen P, van Luxemburg-Heijs SAP, van de Meent M, van Bergen CAM, Halkes CJM, Jedema I, Falkenburg JHF.

Transplantation. 2017 Dec;101(12):2850-2854. doi: 10.1097/TP.0000000000001713.

PMID:
28252558
27.

Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.

Loeff FC, van Egmond HME, Nijmeijer BA, Falkenburg JHF, Halkes CJ, Jedema I.

Leuk Lymphoma. 2017 Sep;58(9):1-14. doi: 10.1080/10428194.2017.1281411. Epub 2017 Jan 31.

PMID:
28140725
28.

Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, Eefting M, von dem Borne PA, van Balen P, Heemskerk MH, Mulder A, Claas FH, Navarrete MA, Honders WM, Rutten CE, Veelken H, Jedema I, Halkes CJ, Griffioen M, Falkenburg JH.

J Clin Invest. 2017 Feb 1;127(2):517-529. doi: 10.1172/JCI86175. Epub 2017 Jan 9.

29.

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.

Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH.

Blood. 2017 Mar 9;129(10):1284-1295. doi: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4.

30.

Plastic CD34 and CD38 expression in adult B-cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations.

Lang F, Wojcik B, Bothur S, Knecht C, Falkenburg JH, Schroeder T, Serve H, Ottmann OG, Rieger MA.

Leukemia. 2017 Mar;31(3):731-734. doi: 10.1038/leu.2016.315. Epub 2016 Nov 2. No abstract available.

31.

Pulmonary immune responses against Aspergillus fumigatus are characterized by high frequencies of IL-17 producing T-cells.

Jolink H, de Boer R, Hombrink P, Jonkers RE, van Dissel JT, Falkenburg JH, Heemskerk MH.

J Infect. 2017 Jan;74(1):81-88. doi: 10.1016/j.jinf.2016.10.010. Epub 2016 Nov 9.

PMID:
27838522
32.

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation.

Lamers CH, Wijers R, van Bergen CA, Somers JA, Braakman E, Gratama JW, Debets R, Falkenburg JH, Cornelissen JJ.

Blood. 2016 Oct 27;128(17):2165-2174. Epub 2016 Aug 16.

33.

Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.

Jahn L, van der Steen DM, Hagedoorn RS, Hombrink P, Kester MG, Schoonakker MP, de Ridder D, van Veelen PA, Falkenburg JH, Heemskerk MH.

Oncotarget. 2016 Nov 22;7(47):77021-77037. doi: 10.18632/oncotarget.12778.

34.

A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.

Jahn L, Hagedoorn RS, van der Steen DM, Hombrink P, Kester MG, Schoonakker MP, de Ridder D, van Veelen PA, Falkenburg JH, Heemskerk MH.

Oncotarget. 2016 Nov 1;7(44):71536-71547. doi: 10.18632/oncotarget.12247.

35.

The Value of Online Algorithms to Predict T-Cell Ligands Created by Genetic Variants.

van der Lee DI, Pont MJ, Falkenburg JH, Griffioen M.

PLoS One. 2016 Sep 12;11(9):e0162808. doi: 10.1371/journal.pone.0162808. eCollection 2016.

36.

Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies.

Pont MJ, Honders MW, Kremer AN, van Kooten C, Out C, Hiemstra PS, de Boer HC, Jager MJ, Schmelzer E, Vries RG, Al Hinai AS, Kroes WG, Monajemi R, Goeman JJ, Böhringer S, Marijt WA, Falkenburg JH, Griffioen M.

PLoS One. 2016 May 12;11(5):e0155165. doi: 10.1371/journal.pone.0155165. eCollection 2016.

37.

Effectivity of a strategy in elderly AML patients to reach allogeneic stem cell transplantation using intensive chemotherapy: Long-term survival is dependent on complete remission after first induction therapy.

von dem Borne PA, de Wreede LC, Halkes CJ, Marijt WA, Falkenburg JH, Veelken H.

Leuk Res. 2016 Jul;46:45-50. doi: 10.1016/j.leukres.2016.03.010. Epub 2016 Apr 9.

38.

Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets.

Griffioen M, van Bergen CA, Falkenburg JH.

Front Immunol. 2016 Mar 15;7:100. doi: 10.3389/fimmu.2016.00100. eCollection 2016. Review.

39.

Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2.

Pont MJ, van der Lee DI, van der Meijden ED, van Bergen CA, Kester MG, Honders MW, Vermaat M, Eefting M, Marijt EW, Kielbasa SM, Hoen PA, Falkenburg JH, Griffioen M.

Clin Cancer Res. 2016 Aug 15;22(16):4185-96. doi: 10.1158/1078-0432.CCR-15-2307. Epub 2016 Mar 10.

40.

Parental Physical Proximity in End-of-Life Care in the PICU.

Falkenburg JL, Tibboel D, Ganzevoort RR, Gischler S, Hagoort J, van Dijk M.

Pediatr Crit Care Med. 2016 May;17(5):e212-7. doi: 10.1097/PCC.0000000000000682.

PMID:
26890197
41.

Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.

Cruijsen M, Hobo W, van der Velden WJFM, Bremmers MEJ, Woestenenk R, Bär B, Falkenburg JHF, Kester M, Schaap NPM, Jansen J, Blijlevens NNM, Dolstra H, Huls G.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1000-1008. doi: 10.1016/j.bbmt.2016.02.003. Epub 2016 Feb 6.

42.

Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.

Eefting M, de Wreede LC, Halkes CJ, von dem Borne PA, Kersting S, Marijt EW, Veelken H, Putter H, Schetelig J, Falkenburg JH.

Haematologica. 2016 Apr;101(4):506-14. doi: 10.3324/haematol.2015.136846. Epub 2016 Jan 22.

43.

Allo-reactive T cells for the treatment of hematological malignancies.

Falkenburg JH, Jedema I.

Mol Oncol. 2015 Dec;9(10):1894-903. doi: 10.1016/j.molonc.2015.10.014. Epub 2015 Oct 24. Review.

44.

T helper 2 response in allergic bronchopulmonary aspergillosis is not driven by specific Aspergillus antigens.

Jolink H, de Boer R, Willems LN, van Dissel JT, Falkenburg JH, Heemskerk MH.

Allergy. 2015 Oct;70(10):1336-9. doi: 10.1111/all.12688. Epub 2015 Aug 6.

PMID:
26179335
45.

LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application.

Pont MJ, Hobo W, Honders MW, van Luxemburg-Heijs SA, Kester MG, van Oeveren-Rietdijk AM, Schaap N, de Boer HC, van Bergen CA, Dolstra H, Falkenburg JH, Griffioen M.

Haematologica. 2015 Oct;100(10):e419-22. doi: 10.3324/haematol.2015.125021. Epub 2015 Jun 11. No abstract available.

46.

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.

Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Marsh JC, Nagler A, Peters C, Velardi A, Mohty M, Madrigal A.

Bone Marrow Transplant. 2015 Aug;50(8):1037-56. doi: 10.1038/bmt.2015.6. Epub 2015 Mar 23. Review.

PMID:
25798672
47.

BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.

Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, Saylors RL, Jedema I, Falkenburg JH, Chambers TC.

Cancer Res. 2015 Apr 1;75(7):1366-75. doi: 10.1158/0008-5472.CAN-14-1849. Epub 2015 Feb 3.

48.

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants.

Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M; European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2015 Apr;50(4):476-82. doi: 10.1038/bmt.2014.312. Epub 2015 Feb 2.

49.

Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach.

Hombrink P, Hassan C, Kester MG, Jahn L, Pont MJ, de Ru AH, van Bergen CA, Griffioen M, Falkenburg JH, van Veelen PA, Heemskerk MH.

Clin Cancer Res. 2015 May 1;21(9):2177-86. doi: 10.1158/1078-0432.CCR-14-2188. Epub 2015 Jan 14.

50.

Monocyte-derived dendritic cells can induce autoreactive CD4(+) T cells showing myeloid lineage directed reactivity in healthy individuals.

Lam TS, van de Meent M, Falkenburg JF, Jedema I.

Eur J Immunol. 2015 Apr;45(4):1030-42. doi: 10.1002/eji.201444819. Epub 2015 Jan 21.

Supplemental Content

Loading ...
Support Center